Navigation Links
Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine

r for use in the management of hemiplegic or basilar migraine. The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominantly male population.

FROVA should only be used when a clear diagnosis of migraine has been established.

As with other drugs in this class, FROVA should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina or other significant underlying cardiovascular disease.

FROVA should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type, as well as transient ischemic attacks.

FROVA should not be given to patients with peripheral vascular disease including (but not limited to) ischemic bowel disease.

FROVA should not be given to patients with uncontrolled hypertension.

It is strongly recommended that FROVA not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease.

It is strongly recommended that patients who are intermittent long-term users of 5-HT1 agonists, including FROVA, and who have or acquire risk factors predictive of CAD, undergo periodic cardiovascular evaluation as they continue to use FROVA.

The development of a potentially life-threatening serotonin syndrome may occur with triptans, including FROVA treatment, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:4/27/2015)... 2015 CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today the appointment ... position of Senior Vice President, Operations, Quality, and Regulatory, ... to Pat Mackin , Chairman, President, and Chief ... is a seasoned industry executive with over 30 years ...
(Date:4/27/2015)... 2015   AMC Health , a leading provider ... monitored care that are transforming chronic care and population ... Conference, May 2-5 at the Los Angeles ... share information about how their innovative programs, solutions and ... personalize healthcare delivery at Booth #2116 and during their ...
(Date:4/27/2015)... , April 27, 2015 PAML announced ... collaborative agreement with Axela, Inc. to develop multiplex ... diseases. PAML is one of the nation,s leading medical ... acid and protein analysis for clinical diagnostics. ... detection strategies, and assay development serves as the ...
Breaking Medicine Technology:CryoLife Appoints William Matthews as Senior Vice President, Operations, Quality, and Regulatory 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
(Date:4/27/2015)... Ticket Down is a reputable source ... Valley Music Theatre and the Isleta Amphitheater. ... Mexico area can celebrate because their favorite performer will ... Buffett will be performing alongside legendary performers, Huey Lewis ... during the summer and fall months of 2015 are ...
(Date:4/27/2015)... 2015 The global coagulation analyzers ... CAGR in developed countries; however, it is expected ... as China, India and Brazil in the next ... is driven by factors such as increasing adoption ... of high-throughput hemostasis analyzers, developments in high-sensitivity point-of-care ...
(Date:4/27/2015)... 2015 Volpara Solutions today announced ... the Society of Breast Imaging’s SBI/ACR Breast Imaging ... Booth #214). VolparaDensity, the first breast density ... breast tomosynthesis datasets from multiple manufacturers, is already ... and worldwide. , The latest version ...
(Date:4/27/2015)... Puroast Coffee has signed on to sponsor the ... BattleFrog OCR is a series of rigorous courses designed by ... the training that Seals undergo, as well as provide a ... to sponsor the BattleFrog events this year,” says Puroast CEO ... well-suited to give people throughout the country the chance to ...
Breaking Medicine News(10 mins):Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 3Health News:Puroast Coffee on Tour with BattleFrog 2
... Reporter , MONDAY, April 18 (HealthDay News) -- New ... stay clear of AIDS longer if they start drug ... However, starting treatment earlier, compared to waiting, didn,t ... benefit in terms of preventing death" by prescribing the ...
... , MONDAY, April 18 (HealthDay News) -- Patients with ... die after surgery, even after non-emergency procedures, a new study ... be used to revive someone who is clinically unresponsive and ... 18 and in the August print issue of the journal ...
... New research finds that older diabetics with better control of ... as heart attacks, amputation and kidney disease. However, ... sugar levels face a slightly higher chance of dying than ... normal range. Researchers tracked more than 70,000 people with ...
... , MONDAY, April 18 (HealthDay News) -- Infection with ... many college students -- and little exposure to sunlight may ... a new study suggests. "MS is more common at ... researcher, Dr. George C. Ebers, of the University of Oxford ...
... ovarian cancer (HGSOC), the fifth-deadliest cancer among American women, ... fallopian tube malignancy masquerading as an ovarian one. While ... tubes has so far been only circumstantial, a new ... connection, a finding that could aid in the development ...
... Ill. Nearly 800 dental sleep medicine professionals from ... Meeting of the American Academy of Dental Sleep Medicine ... at the Hilton Minneapolis in Minneapolis, Minn. The meeting ... 25th Anniversary Meeting of the Associated Professional Sleep Societies. ...
Cached Medicine News:Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 2Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 3Health News:People With DNR Orders More Apt to Die After Any Surgery 2Health News:Low Glucose Levels May Raise Death Risk Among Older People 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: